Cargando…

Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients

Anti-PD-1 antibodies revolutionized the treatment of advanced melanoma patients. However, one out of three do not respond to this therapy, with an overall poor prognosis. Identification of predictive biomarkers in patients receiving immune-based therapies is necessary for minimizing risk of toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giunta, Emilio Francesco, Barra, Giusi, De Falco, Vincenzo, Argenziano, Giuseppe, Napolitano, Stefania, Vitale, Pasquale, Zanaletti, Nicoletta, Terminiello, Marinella, Martinelli, Erika, Morgillo, Floriana, Ciardiello, Davide, De Palma, Raffaele, Ciardiello, Fortunato, Troiani, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573589/ https://www.ncbi.nlm.nih.gov/pubmed/33077770 http://dx.doi.org/10.1038/s41598-020-72711-2

Ejemplares similares

Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’
por: De Falco, Vincenzo, et al.
Publicado: (2020)

Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience
por: Vitiello, Pietro Paolo, et al.
Publicado: (2019)

Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care
por: Martinelli, Erika, et al.
Publicado: (2007)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011)

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
por: Troiani, Teresa, et al.
Publicado: (2016)

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models
por: Belli, Valentina, et al.
Publicado: (2019)

Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature
por: Viscardi, Giuseppe, et al.
Publicado: (2019)

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
por: De Falco, Vincenzo, et al.
Publicado: (2019)

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
por: Vitiello, Pietro Paolo, et al.
Publicado: (2019)

Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation
por: Napolitano, Stefania, et al.
Publicado: (2017)

Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 Pandemic
por: Napolitano, Stefania, et al.
Publicado: (2022)

Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer
por: Belli, Valentina, et al.
Publicado: (2017)

Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

Towards the era of precision medicine in metastatic colorectal cancer
por: Napolitano, Stefania, et al.
Publicado: (2020)

Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype
por: Ciardiello, Davide, et al.
Publicado: (2021)

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells
por: Napolitano, Stefania, et al.
Publicado: (2017)

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression
por: Napolitano, S., et al.
Publicado: (2019)

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets
por: Martini, Giulia, et al.
Publicado: (2017)

Role and targeting of anaplastic lymphoma kinase in cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018)

Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC
por: Ciaramella, Vincenza, et al.
Publicado: (2019)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
por: Vitiello, Pietro Paolo, et al.
Publicado: (2021)

Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results
por: Troiani, Teresa, et al.
Publicado: (2021)

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
por: Della Corte, Carminia Maria, et al.
Publicado: (2019)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
por: Fasano, Morena, et al.
Publicado: (2022)

Implication of the Hedgehog pathway in hepatocellular carcinoma
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Mechanisms of resistance to EGFR-targeted drugs: lung cancer
por: Morgillo, Floriana, et al.
Publicado: (2016)

Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives
por: Ciaramella, Vincenza, et al.
Publicado: (2018)

How we treat metastatic colorectal cancer
por: De Falco, Vincenzo, et al.
Publicado: (2020)

Diagnostic value/performance of radiological liver imaging during chemoterapy for gastrointestinal malignancy: a critical review
por: Alfonso, Reginelli, et al.
Publicado: (2019)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Corte, Carminia Maria Della, et al.
Publicado: (2022)

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
por: Caputo, Vincenza, et al.
Publicado: (2022)

Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy
por: Fasano, Morena, et al.
Publicado: (2015)

Role of HGF–MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2014)

Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme
por: Sforza, Vincenzo, et al.
Publicado: (2017)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941
por: Ciardiello, Davide, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_icpi3cssdtsgmt2crggpeunfvo